{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-014115","form_type":"8-K","ticker":"ORKA","cik":"0000907654","company_name":"Oruka Therapeutics, Inc.","filed_at":"2023-04-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.744896+00:00","generated_at":"2026-06-16T20:50:04.249454+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ARCA biopharma reports Q1 net loss of $1.3M; strategic review ongoing","bullets":["Net loss of $1.3M ($0.09 per share) vs $3.3M ($0.23) in Q1 2022; improvement due to lower R&D costs.","Cash and equivalents $40.9M as of March 31, 2023, expected to fund operations through mid-2024.","Strategic review process continues with Ladenburg Thalmann; evaluating merger, asset sale, or other options.","R&D expenses fell to $0.4M from $2.2M YoY after enrollment completion in rNAPc2 Phase 2b trial.","G&A expenses rose to $1.4M from $1.1M, including $159K severance for former General Counsel."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-014115","json":"https://secwatch.observer/filing/0000950170-23-014115.json","markdown":"https://secwatch.observer/filing/0000950170-23-014115.md","text":"https://secwatch.observer/filing/0000950170-23-014115.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/907654/000095017023014115/0000950170-23-014115-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/907654/000095017023014115/abio-20230424.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T20:50:04.249454+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"999bd53f10e7334c88278045020436afb3cd27ca","claim":"Oruka Therapeutics, Inc. reported the quarter ended March 31, 2023 results: net income $1.3 million, EPS $0.09 per basic and diluted share.","evidence_excerpt":"Net loss for the quarter ended March 31, 2023 was $1.3 million, or $0.09 per basic and diluted share, compared to $3.3 million, or $0.23 per basic and diluted share in the first quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/907654/000095017023014115/0000950170-23-014115-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Net income","value":"$1.3 million"},{"label":"EPS","value":"$0.09 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}